ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: liver

Sarilumab Is Effective for RA, Pregabalin Fails to Meet Study Endpoint & Ibuprofen Can Be Administered with a Patch

Michele B. Kaufman, PharmD, BCGP  |  January 13, 2016

Sarilumab is proving effective for treating RA. In a clinical trial, pregabalin did not meet its endpoint for treating post-traumatic peripheral neuropathic pain. And a 12-hour ibuprofen patch is in development…

Filed under:AnalgesicsBiologics/DMARDsDrug Updates Tagged with:Painperipheral neuropathic painpregabalinRheumatoid Arthritis (RA)sarilumab

Living with RA: Study Examines the Value of Patient Involvement in Creating Clinical Practice Guidelines

Arthritis Care & Research  |  January 6, 2016

“The lived experience with RA is itself a valuable form of expertise,” writes Dr. Liana Fraenkel, MD, MPH, and her colleagues in their latest research. To examine the value of this expertise and how it can be incorporated into clinical practice guidelines, researchers developed 18 questions for which two panels—one physician dominated and one comprising entirely patients—would develop recommendations. For a majority of these questions, the patient panel made the same recommendations as the physician panel, with similar recommendation strengths…

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:Arthritis Care & ResearchClinical Practice GuidelinesPatientsRheumatoid Arthritis (RA)

New President Dr. Von Feldt Looks at Where ACR Is Headed in 2016

Joan M. Von Feldt, MD, MSEd, FACR, FACP  |  December 17, 2015

I am honored, humbled and excited to serve as your ACR president. I’d like to share the following background information to illustrate the diverse set of life experiences I draw from to represent the ACR membership effectively. Personal Background Thanks to my mom, who was born and raised in Guatemala, I am bilingual in Spanish…

Filed under:President's Perspective Tagged with:AC&RAdvocacyAmerican College of Rheumatology (ACR)Practice Managementprogressrheumatologytransformation

Looking Back on Rheumatology in 2015, Leaping Forward to the Year Ahead

Simon M. Helfgott, MD  |  December 16, 2015

My dear friends, we come to praise Caesar. As we march toward 2016, we ought to acknowledge the great Roman emperor’s role in creating a proper calendar. At the start of Caesar’s reign, the calendar year lasted 355 days, 10¼ days fewer than the time it took the earth to fully orbit the sun.1 Although…

Filed under:Legislation & AdvocacyOpinionPractice SupportProfessional TopicsRheuminationsSpeak Out Rheum Tagged with:Legislation & AdvocacyPractice ManagementProfessional TopicsRheuminations

A Brief History of American Rheumatology

Maria J. Antonelli, MD, Cassandra M. Calabrese, DO, Leonard H. Calabrese, DO, & Irving Kushner, MD  |  December 16, 2015

In medicine, as in all other areas of human endeavor, we cannot really understand where we are if we don’t understand how we arrived here. American rheumatology traces its origins nine decades back to Europe, when the International Committee on Rheumatism was founded by Jan van Breeman in 1925 at a European meeting of medical…

Filed under:Professional Topics Tagged with:Historyrheumatology

Hospital Safety Culture Key to Improving Surgical Results

Megan Brooks  |  December 15, 2015

NEW YORK (Reuters Health)—The “safety culture” of a hospital may be just as important in delivering high-quality surgical patient care as more technical issues like surgeon skill and operating room equipment, according to a new study. “The study supports what many surgeons have known for a long time, and that is that the organizational culture…

Filed under:FacilityPractice Support Tagged with:hospitalSafetysurgery

FDA Approves Drug to Counter Opioid ODs

Michele B. Kaufman, PharmD, BCGP  |  December 9, 2015

The FDA recently approved a form of naloxone hydrochloride in a nasal spray that will help counter opioid overdoses. The FDA also approved an ibuprofen injection as an adjunct to opioids for use in children 6 months and older…

Filed under:AnalgesicsDrug Updates Tagged with:FDAFood and Drug AdministrationIbuprofenNaloxone hydrochlorideOpioidsOverdosePainPediatrics

Advocating with You—Grassroots Advocacy: Media Outreach 101

From the College  |  December 8, 2015

Rheumatologists must speak for themselves and their patients, because no one else will speak for us. Advocacy is necessary to educate elected officials and preserve our ability to provide the best care to our patients. One way to reach these officials is through the local media. Here are some tips on how to reach out to reporters, write op-eds and letters, and become a knowledgeable resource for your community…

Filed under:From the CollegeLegislation & AdvocacyProfessional Topics Tagged with:AdvocacyMedia

Amgen Files for U.S. Approval of Biosimilar

Bill Berkrot  |  November 29, 2015

(Reuters)—Amgen Inc. on Wednesday said it filed with U.S. health regulators seeking approval to sell its first biosimilar drug, which would be a less expensive alternative to AbbVie’s Humira (adalimumab), the world’s top-selling prescription medicine. Amgen said its drug, ABP 501, has demonstrated clinical equivalence and comparable safety to Humira in late stage clinical trials…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabAmgenBiosimilarsFDAFood and Drug Administration

Obama Nominee to Lead FDA Defends Drug Industry Ties

Toni Clarke  |  November 17, 2015

(Reuters)—President Barack Obama’s nominee to head the U.S. Food and Drug Administration defended his ties to the pharmaceutical industry on Tuesday during a Senate committee hearing that included questions on soaring drug prices. Presidential candidate Bernie Sanders was among the Democrats who grilled Dr. Robert Califf (64), who joined the FDA in January as a…

Filed under:Drug UpdatesLegislation & Advocacy Tagged with:CongresscostsdrugFDAFood and Drug Administration

  • « Previous Page
  • 1
  • …
  • 83
  • 84
  • 85
  • 86
  • 87
  • …
  • 128
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences